We investigated aging of human endogenous reparative capacity and aimed to clarify whether it is affected by presence of cardiovascular disease or its risk factors.
INTRODUCTION
Age is an overarching risk factor (RF) for development of the majority of chronic noncommunicable diseases including cardiovascular diseases (CVD). Aside from prolonging exposure to atherosclerotic RFs, increasing age causes distinct changes in cardiovascular tissues that include arterial medial/intimal thickening and pathologic derangements in endothelial and myocardial cells that culminate in vascular and cardiac dysfunction. Superimposition of RFs accelerates these processes leading to premature aging of the cardiovascular system and early development of CVD.
A pivotal response to experimental vascular injury is the recruitment of bone marrow and tissue progenitor cells (PC) to participate in repair and regeneration. A rare population of bone-marrow mononuclear cells expressing the CD34 epitope are enriched for PC. They have the potential to differentiate into hematopoietic, endothelial, and other lineages and aid in vascular and myocardial repair and regeneration. [1] [2] [3] [4] [5] CD34-expressing mononuclear cells include hematopoietic and endothelial PC, as well as non-hematopoietic (mesenchymal, lacking CD45 expression) PC. 6 CD133 is a 5-transmembrane antigen of primitive stem cells that is lost during maturation, and CD34 negative cells expressing CD133 differentiate into CD34+ cells with greater proliferative activity. Thus, dual expression of these markers (CD34+/CD133+) identifies a PC-enriched subpopulation. 3, 7 Co-expression of vascular endothelial growth factor receptor-2 (VEGFR2) appears to identify a rarer subpopulation of PC further enriched for either endothelial or hematopoietic progenitors. [8] [9] [10] Finally, co-expression of CXCR4, which promotes homing of PC to stromal-derived factor-enriched hypoxic environments, may further characterize PC with capacity for tissue repair. 11 on the presence of hypertension, hypercholesterolemia, diabetes mellitus, and smoking, and/or overt CVD. Overall, increasing RF burden was associated with significantly higher circulating counts of CD34+ and CD34+/CD133+ cells (p<0.0001 for both) but with the other cell populations. (Figure 2 ). These associations were mainly driven by subjects 55 years of age or older, and were not evident in younger individuals, in which an opposite trend was in fact noted for CD34+/CXCR+ and CD34+/CD133+/CXCR+ cells (p=0.25 and 0.18; respectively). Thus, while increasing burden of cardiovascular RF correlated with diminished PC counts in older individuals, this was not observed in younger individuals. (Figure 2 ).
Relationship between age, RF burden and PC counts.
Unadjusted analyses of the relationship between age and PC populations in all subjects and in groups with increasing RF burden appears in Table 3 . While the age-related decline in circulating counts of all PC subtypes in the overall population, subjects with no RF (N=498) exhibited no significant differences in CD34+, CD34+/CXCR4+ or CD34+/VEGFR2+ counts (p=0.08, 0.17 and 0.15; respectively) with increasing age. (Table 3 ). Overall, the univariate correlations between age and PC counts were progressively more robust in groups with higher RF burden. (Table 3 ).
Interaction analyses:
As the above findings suggested that age may exert substantial interaction effects on the relationship between RF burden and PC counts, we sought to determine whether age-related decline in PC counts is affected by RF burden after multivariate adjustment. Linear regression models with log-transformed PC counts as the response variable; and age, RF group, and age x RF group interaction term as the explanatory variables were constructed, with gender, BMI, and statin use entered as covariates. Full results of multiple linear regression analyses can be seen in the supplemental section. (Online table II) .
Estimates of age-related decreases in PC counts with increasing age among the three risk groups, after multivariate adjustment, demonstrate significantly differing age-slopes for the three RF groups, confirming an interaction between age and RF burden on PC counts. (Figure 3) . Similarly, the adjusted percent decline in PC counts per decade of increasing age for CD34+, CD34+/CD133+, CD34+/CXCR4+, and CD34+/CD133+/CXCR4+ cells among the three RF groups is presented in Table 4 , and is significantly larger with increasing RF burden for all PC subtypes except for the CD34+/CD133+/CXCR4+ cell population. (Table 4) . Thus, whereas, for each 10-year increase in age, the CD34+ cell counts decreased by 2.6% in those without RFs, subjects with 3 or more RF exhibited a significantly more precipitous decline of 12.6% per decade.
DISCUSSION
In a large population study that included healthy subjects, those with RFs and overt CVD, we demonstrate that age-related differences in circulating PC numbers are significantly modulated by CVD risk burden, independent of gender, body size and statin use. Although there was an overall age-related decline in PC counts in the entire population, the presence of CVD RFs significantly modified this relationship such that healthy subjects with no RFs exhibited no significant changes or small declines in PC counts with increasing age, while groups with higher CVD RF burden had progressively steeper age-related declines in most PC subsets. Furthermore, whereas the presence of RFs in subjects younger than 55 years was not associated with decreases in blood PC counts, significantly lower numbers of circulating PC were observed in older subjects with higher RF burden. Taken together, these novel findings suggest that protracted exposure to injurious effects of CVD and its RFs over the lifespan might result in exhaustion in circulating PC.
Several techniques are available for assessing PC number and function, including evaluation of in vitro growth and mobility potential. 3, 22 Measurement of the number of circulating PC as in this study is nevertheless readily available, is reproducible, and amenable for performance in large scale studies. We employed a robust flow-cytometric technique for evaluation of PC-enriched populations. In addition to CD34+ cells, we examined sub-populations that co-expressed CD133, VEGF2R, and CXCR4 in order to identify cell populations that are enriched for various putative progenitors. CD133 co-expression identifies an early progenitor subset, VEGF2R expression identifies PCs enriched for endothelial progenitors, and the CXCR4 receptor binds to the highly chemotactic and angiogenic stromal derived factor-1 responsible for PC homing. 28, 29 The large number and wide age range of subjects in each risk category permitted examination of PC counts at different ages in healthy subjects and in those with RFs or with established CVD. Notably, hematopoietic PC populations expressing CD34 and those co-expressing CD133+ and/or CXCR4+ showed a similar decline with increasing age and RF burden. In contrast, VEGF2R+ cells that are enriched for endothelial PC, exhibited either none or weak associations that may be partly due to their relatively rare numbers and/or relatively higher measurement variability.
The notion that cardiovascular risk influences aging of regenerative capacity in humans is supported by experimental studies demonstrating age-related decline in peripheral blood and bone marrow PC, both numerically and functionally, that is accelerated in the atherosclerotic milieu. Also, the atheroprotective property of bone marrow PC was shown to be exhausted with increasing age and exposure to RFs in a murine model of atherosclerosis resulting in deficient vascular repair. 30, 31 Human studies also support our findings. Lower frequency of circulating CD34+ cells with increasing CVD risk burden was reported in subjects recruited in the Framingham Heart Study with a mean age of 66 years, findings similar to our observations in the >55 years of age cohort. 32 Our study however also included a large number of younger and healthier subjects, revealing the relationship between PC and RFs in the younger cohorts. Our findings of higher CD34+ counts in younger subjects, men and in hypertensives, as well as with increasing body size, higher triglycerides and lower high-density lipoprotein levels have been previously reported, and we extend these results to other circulating PC subpopulations co-expressing CD133 and CXCR4. 32 Overall, emerging experimental and clinical data suggest that recruitment of bone marrow PC and mobilization into the circulation is a homeostatic response to vascular injury that is preserved in young and healthy individuals and diminishes with aging and chronic RF exposure. Moreover, depressed PC numbers and function in the presence of CVD is associated with adverse outcomes. 33-35 Furthermore, PC mobilization after tissue injury such as acute myocardial infarction, or in response to cytokine administration is blunted with increasing age and RF exposure in humans, and the potential of transplanted bone marrow PC to effect neovascularization is impaired with aging. [36] [37] [38] [39] Our findings are relevant for the field of regenerative medicine. Herein, we demonstrate that PC counts in the circulation, as an index of endogenous regenerative capacity, should be assessed after accounting for an individual's age, gender, body size, and RF burden. Specifically, older subjects with the combination of RFs and lower PC content in their blood may be appropriate subjects for novel cell-based therapeutic studies that involve PC mobilization or bone marrow isolation and expansion. 12, 13, 40 In the context of CVD risk prediction, we have previously demonstrated that lower counts of circulating PC in patients with suspected CAD were prospectively associated with increased morbidity and mortality. 34 Similarly, whether lower counts in younger individuals confer future protection from CVD needs further investigation.
Limitations.
The cross-sectional design of our study precludes definitive conclusions regarding the causal relationships between PC and CVD RFs. Similarly, we cannot conclude that aging with RFs leads to exhaustion of circulating PC, although these findings have been validated in experimental models. The contribution of other comorbidities or organ dysfunction, as well as effects of pharmacologic therapy were not evaluated in this study and will be worthy of further investigations in longitudinal studies.
Conclusion.
Our results suggest that CVD RFs modulate aging of human regenerative capacity, whereby increasing RF burden is associated with a greater age-related decline in PC counts, which may be due to exhaustion of endogenous regenerative capacity. In subjects free of CVD RFs or CVD, circulating levels of hematopoietic PC do not change appreciably with increasing age. Exposure to injurious CVD RFs at a young age is not associated with decreased PC counts; however, with aging, continued exposure to RFs leads to reduction in PC levels and consequent exhaustion of endogenous regenerative capacity. Lavazais 
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Figure 2: Cardiovascular risk factor burden and PC counts in younger vs. older subjects.
Effects of RF burden on PC counts in younger vs. older subjects. Estimated mean ± standard error PC counts with increasing cardiovascular risk factor burden in subjects > 55 years of age (N=1592) compared to those ≤ 55 years old (N=1200). Estimates were obtained by setting gender as female, BMI=28 kg/m2, and no statin use. P-values are for comparisons among three risk groups.
Figure 3: Effects of increasing risk factor burden on age-related decline of PC counts.
Decreases in PC counts with increasing age among the three risk groups. P-values for the age effect on PC counts are shown for each risk group. All analyses were adjusted for gender, BMI, and statin use. *p ≤ 0.05 compared with no RF group, **p < 0.0001 compared with no RF group. RF: Risk factors
Novelty and Significance
What Is Known?
 Bone marrow and tissue progenitor cells (PC) participate in vascular repair and regeneration.
 Some studies have reported that tissue injury mobilizes PC into the circulation and depressed PC activity in the presence of cardiovascular disease (CVD).
 It is unclear whether "healthy aging" with significant CVD risk affects the mobilization of PC and their circulating counts.
What New Information Does This Article Contribute?
The interaction between age and risk factor burden significantly affects their relationship with circulating levels of PC.
 Healthy aging is accompanied by non-significant changes in PC counts and worsening risk factor burden is associated with a precipitous age-related decline in the circulating levels of most PC subsets.
 Cardiovascular disease risk accelerates the aging of human regenerative capacity and healthy aging is characterized by preservation of PC activity.
Age is an overarching risk factor for the development of CVD. However, it is unclear how aging alters circulating PC numbers, and whether atherosclerosis impairs PC. We investigated the relationship between healthy aging as well as aging with CVD risk burden or established CVD on PC levels. We found that increasing CVD risk burden was accompanied by a precipitous age-related decline in circulating PC counts, reflecting exhaustion of endogenous regenerative capacity. Conversely, in subjects free of CVD risk factors circulating levels of PC do not change appreciably with age. These findings suggest that for CVD risk prediction PC activity should be assessed in the context of an individual's age, gender, body size, and risk factor burden. Estimated differences in mean CD34+, CD34+/CD133+, CD34+/CXCR4+, CD34+/CD133+/CXCR4+ and CD34+/VEGF2R+ per 10-years age increase for the three risk groups, after adjusting for gender, BMI, and statin use (N=2787). *Test for difference in age-related changes in PC counts among three risk groups.
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